ProQR Therapeutics NV reports results for the quarter ended in March - Earnings Summary

ProQR Therapeutics NV

06/05/2021 16:36

* ProQR Therapeutics NV  PRQR.OQ  reported a quarterly adjusted
loss of 30 cents​​ per share for the quarter ended in March. The
mean expectation of six analysts for the quarter was for a loss
of 30 cents per share.
* Revenue fell 46.4% to $169.27 thousand from a year ago​; 
analysts expected $547.83 thousand.
* ProQR Therapeutics NV's reported EPS for the quarter was a
loss of 30 cents​.
* The mean earnings estimate of analysts had risen by about 5.6%
in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* ProQR Therapeutics NV shares had fallen by 6.4% this
quarter and gained 47.4% so far this year.
* The company reported a quarterly loss of $14.66 million.
* Wall Street's median 12-month price target for ProQR
Therapeutics NV is $21.50 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 8 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated May 6 at 03:36 p.m. GMT. ​All
figures in US Dollars.​